GSK exercises option on two Galapagos candidates
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has exercised its option to exclusively license GLPG0778 and a back-up compound GLPG0555 discovered through its immuno-inflammatory alliance with Belgium's Galapagos.